Thrombosis and Haemostasis, Inhaltsverzeichnis Thromb Haemost 2008; 99(01): 133-141DOI: 10.1055/s-0037-1608919 Endothelium and Vascular Development Schattauer GmbH Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells Yona Nadir 1 Cancer and Vascular Biology Research Center, The Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel 2 Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Medical Center, Haifa, Israel , Benjamin Brenner 2 Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Medical Center, Haifa, Israel , Sveta Gingis-Velitski 1 Cancer and Vascular Biology Research Center, The Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel , Flonia Levy-Adam 1 Cancer and Vascular Biology Research Center, The Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel , Neta Ilan 1 Cancer and Vascular Biology Research Center, The Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel , Eyal Zcharia 3 Department of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel , Erez Nadir 4 Department of Neonatology, Hillel Yaffe Medical Center, Hadera, Israel , Israel Vlodavsky 1 Cancer and Vascular Biology Research Center, The Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel › Institutsangaben Artikel empfehlen Abstract Volltext als PDF herunterladen Keywords KeywordsTFPI - heparanase - coagulation - endothelial cells - tumor Referenzen References 1 Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471: M99-108. 2 Vlodavsky I, Abboud-Jarrous G, Elkin M. et al. The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 2006; 35: 116-127. 3 Bar-Sela G, Kaplan-Cohen V, Ilan N. et al. Heparanase expression in nasopharyngeal carcinoma inversely correlates with patient survival. Histopathology 2006; 49: 188-193. 4 Koliopanos A, Friess H, Kleeff J. et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001; 61: 4655-4659. 5 Rohloff J, Zinke J, Schoppmeyer K. et al. Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma. Br J Cancer 2002; 86: 1270-1275. 6 Gohji K, Hirano H, Okamoto M. et al. Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer 2001; 95: 295-301. 7 Takaoka M, Naomoto Y, Ohkawa T. et al. Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest 2003; 83: 613-622. 8 Tang W, Nakamura Y, Tsujimoto M. et al. Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol 2002; 15: 593-598. 9 Shinyo Y, Kodama J, Hongo A. et al. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol 2003; 14: 1505-1510. 10 Sato T, Yamaguchi A, Goi T. et al. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J Surg Oncol 2004; 87: 174-181. 11 Gingis-Velitski S, Zetser A, Flugelman MY. et al. Heparanase Induces Endothelial Cell Migration via Protein Kinase B/Akt Activation. J Biol Chem 2004; 279: 23536-23541. 12 Zetser A, Bashenko Y, Edovitsky E. et al. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006; 66: 1455-1463. 13 Elkin M, Ilan N, Ishai-Michaeli R. et al. Heparanase as mediator of angiogenesis: mode of action. Faseb J 2001; 15: 1661-1663. 14 Nadir Y, Brenner B, Zetser A. et al. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 2006; 4: 2443-2451. 15 Gingis-Velitski S, Zetser A, Kaplan V. et al. Heparanase Uptake Is Mediated by Cell Membrane Heparan Sulfate Proteoglycans. J Biol Chem 2004; 279: 44084-44092. 16 Zetser A, Bashenko Y, Miao H-Q. et al. Heparanase Affects Adhesive and Tumorigenic Potential of Human Glioma Cells. Cancer Res 2003; 63: 7733-7741. 17 Zetser A, Levy-Adam F, Kaplan V. et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004; 117: 2249-2258. 18 Hulett MD, Hornby JR, Ohms SJ. et al. Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 2000; 39: 15659-15667. 19 Levy-Adam F, Abboud-Jarrous G, Guerrini M. et al. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 2005; 280: 20457-20466. 20 Nardella C, Lahm A, Pallaoro M. et al. Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 2004; 43: 1862-1873. 21 Zcharia E, Metzger S, Chajek-Shaul L T. et al. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tis- sue morphogenesis, vascularization, and feeding behavior. FASEB J 2004; 18: 252-263. 22 Ho G, Broze Jr GJ, Schwartz AL. Role of heparan sulfate proteoglycans in the uptake and degradation of tissue factor pathway inhibitor-coagulation factor Xa complexes. J Biol Chem. 1997: 16838-16844. 23 Fuki II, Iozzo RV, Williams KJ. Perlecan heparan sulfate proteoglycan. A novel receptor that mediates a distinct pathway for ligand catabolism. J Biol Chem 2000; 275: 25742-50. 24 Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006; 208: 327-339. 25 Iversen N, Lindahl AK, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol 1998; 102: 889-895. 26 Gerlach R, Scheuer T, Bohm M. et al. Increased levels of plasma tissue factor pathway inhibitor in patients with glioblastoma and intracerebral metastases. Neurol Res 2003; 25: 335-338. 27 Shafat I, Zcharia E, Nisman B. et al. An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 2006; 341: 958-963. 28 Vlodavsky I, Eldor A, Haimovitz-Friedman A. et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 1992; 12: 112-127. 29 Haim N, Lanir N, Hoffman R. et al. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001; 110: 91-96. 30 Hoke M, Kyrle PA, Minar E. et al. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost 2005; 94: 787-790. 31 Sarig G, Blumenfeld Z, Leiba R. et al. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. Thromb Haemost 2005; 94: 980-985. 32 Mousa SA, Linhardt R, Francis JL. et al. A. Antimetastatic effect of a non-anticoagulant low-molecular- weight heparin versus the standard low-molecularweight heparin, enoxaparin. Thromb Haemost 2006; 96: 816-21. 33 Hostettler N, Naggi A, Torri G. et al. P-selectin- and heparanase-dependent antimetastatic activity of nonanticoagulant heparins. FASEB J 2007; 21: 3562-3572. 34 Liu T, Scallan CD, Broze Jr GJ. et al. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP). Thromb Haemost 2006; 95: 68-76. 35 Naggi A, Casu B, Perez M. et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 2005; 280: 12103-12113.
